The Effect of Curcumin Supplementation on Recovery From Exercise-induced Muscle Damage

NCT ID: NCT05346211

Last Updated: 2022-04-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-05-01

Study Completion Date

2023-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Recent evidence suggests that curcumin supplementation may reduce muscle inflammation, oxidative markers, and muscle damage. The most favourable dosage to elicit these ergogenic effects are yet to be established; both 750mg \& 1500mg has been shown to be effective. Curcumin supplementation has been ingested in numerous different ways however, no previous research to date has used curcumin in a hydrolysed (drinkable) format. The aim of this study is to investigate whether hydrolysed curcumin can reduce indices of muscle damage and improve recovery, whilst also examining a potential dose-response effect.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Exercise Induced Muscle Damage

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Curcumin Single

The Single dose group will consume 1 placebo sachet and one curcumin sachet per day.

Curcumin supplementation will be from YourZooki, the supplement in question is commercially offered to the public in a tangerine flavour. The sachets will be in 750mg hydrolysed format.

The placebo is a sachet containing the same ingredients mentioned above minus the curcumin. The sachets will be in 750mg hydrolysed format.

Supplementation will be administered and commence 48-hours prior to the first testing day and will be consumed twice a day (8am \& 8pm).

Group Type EXPERIMENTAL

Curcumin

Intervention Type DIETARY_SUPPLEMENT

Curcumin Supplementation

Curcumin Double

The double dose group will consume two sachets per day of curcumin.

Curcumin supplementation will be from YourZooki, the supplement in question is commercially offered to the public in a tangerine flavour. The sachets will be in 750mg hydrolysed format.

Supplementation will be administered and commence 48-hours prior to the first testing day and will be consumed twice a day (8am \& 8pm).

Group Type EXPERIMENTAL

Curcumin

Intervention Type DIETARY_SUPPLEMENT

Curcumin Supplementation

Placebo

Placebo sachets containing the same ingredients mentioned above minus the curcumin. The sachets will be in 750mg hydrolysed format.

Participants will consume two sachets per day.

Supplementation will be administered and commence 48-hours prior to the first testing day and will be consumed twice a day (8am \& 8pm).

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Curcumin

Curcumin Supplementation

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* between the age of 18-35
* non-smoker
* no previous history of cardiovascular, respiratory, or neurological problems
* not taking anticoagulant medication
* injury-free in the 3 months prior to scheduled participation in the study

Exclusion Criteria

* hypertension (\<140/80)
* any blood diseases or clotting issues,
* injury, or previous injury in \<3 months
Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

St Mary's University College

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Luke Hughes, PhD

Role: PRINCIPAL_INVESTIGATOR

Northumbria University

Jess Hill, PhD

Role: PRINCIPAL_INVESTIGATOR

St. Mary's University, Twickenham

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Luke Hughes, PhD

Role: CONTACT

+447920004214

Ian Grant, MSc

Role: CONTACT

020 8240 4000

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ASE22HELCON

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

HMB and Exercise-induced Muscle Damage
NCT04549610 RECRUITING PHASE2/PHASE3